Somatostatin analogs for the treatment of neuroendocrine tumors.
about
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsThe somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cellsEvaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysisManagement of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.A knockin mouse model for human ATP4aR703C mutation identified in familial gastric neuroendocrine tumors recapitulates the premalignant condition of the human disease and suggests new therapeutic strategies.Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug.Pancreatic neuroendocrine tumors: a comprehensive review.Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges.Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.Imaging, biodistribution and efficacy evaluation of 188Re-human serum albumin microspheres via intraarterial route in an orthotopic hepatoma model.Activation of somatostatin 2 receptors in the brain and the periphery induces opposite changes in circulating ghrelin levels: functional implications.Effects of octreotide therapy in progressive head and neck paragangliomas: case series.⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma.Truncated variants of pig somatostatin receptor subtype 5 (sst5) act as dominant-negative modulators for sst2-mediated signaling.Biodistribution, Pharmacokinetics and Efficacy of 188Re(I)-Tricarbonyl-Labeled Human Serum Albumin Microspheres in an Orthotopic Hepatoma Rat Model.
P2860
Q26862544-4AD14225-969A-4EAF-A81B-53BC0955A6B8Q28484664-519BAB42-1B81-4065-9906-6D3018B7752AQ35681825-4E76E86D-C0A0-47AE-BC5C-5B0AD125E780Q36184629-C55AD17F-0A67-4E23-A691-F4715A832679Q36536629-FF5E2ED4-BA4D-4449-BDE1-C26A880458F8Q36565634-1191E218-B0EA-4E11-B1A2-6E4945D032F6Q37305896-B8DCA5BA-B1E7-498D-996A-06DB0855B0F7Q37624511-F754839E-5912-4934-BCEA-B36ECFF24AD4Q37983497-BF2D5DCC-B514-47D6-ACA0-7FCCB1B9B2F6Q37995947-0475C42E-5F72-433D-B342-43F74116A69CQ38010424-CCF31C07-09F9-403D-9CB0-53601859D3BFQ38132768-8EA4F144-5D04-4C3E-8F98-F00F8C9E770DQ38175857-A233E9E1-5844-4B52-B43E-1856BFA789A2Q38674812-88BF3751-F537-4918-89E3-ACFC43FAEC82Q38723174-7ED51E94-FD90-4647-B650-B7D0D21A701FQ42519592-A80D812E-C000-4393-9E97-F7C1B216D96DQ43755698-4E3FAAC0-D59B-497E-807B-A3E8E0DFFA02Q44209015-D162A138-DFB7-4B86-BC5D-FF3CCA9C73D7Q50933634-AB5F5BF1-655A-4669-BDF7-0AB9205B646AQ51756591-8F8D65F2-6BEC-4681-A920-BA8241A33FC1Q55504888-3B0A1EAF-98EA-4380-A2BC-B76BF765AD09
P2860
Somatostatin analogs for the treatment of neuroendocrine tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Somatostatin analogs for the treatment of neuroendocrine tumors.
@en
Somatostatin analogs for the treatment of neuroendocrine tumors.
@nl
type
label
Somatostatin analogs for the treatment of neuroendocrine tumors.
@en
Somatostatin analogs for the treatment of neuroendocrine tumors.
@nl
prefLabel
Somatostatin analogs for the treatment of neuroendocrine tumors.
@en
Somatostatin analogs for the treatment of neuroendocrine tumors.
@nl
P2093
P2860
P1476
Somatostatin analogs for the treatment of neuroendocrine tumors
@en
P2093
Eric P Krenning
Isabel Sevilla
José Angel Díaz
Kjell Oberg
Rudolf Arnold
P2860
P2888
P356
10.1007/S10555-011-9293-0
P478
30 Suppl 1
P577
2011-03-01T00:00:00Z